Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

BMC Neuroscience

Volumn 14, Issue , 2013, Pages

  Chen, Yan ^a   Ni, Ying Yin ^a   Liu, Jie ^c   Lu, Jia Wei ^a   Wang, Fang ^a   Wu, Xiao Lin ^a   Gu, Ming Min ^a   Lu, Zhen Yu ^a   Wang, Zhu Gang ^a,c,d   Ren, Zhi Hua ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d Shanghai Research Center for Model Organisms   (China)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine induced neurotoxicity; Dopamine receptor 3; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 3 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYKINESIA; BRAIN NERVE CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSKINESIA; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MPTP POISONING; PSYCHOMOTOR PERFORMANCE; RECEPTORS, DOPAMINE D3; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84880856354     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-14-76     Document Type: Article

References (25)

1. Sian J, Youdim M, Riederer P, Gerlach M. MPTP-induced parkinsonian syndrome, basic neurochemistry. Molecular, Cellular and Medical Aspects 1999, Philadelphia: Lippincott-Raven, Siegel GJ, 6.
2. Kopin I. Features of the dopaminergic neurotoxin MPTP. Ann N Y Acad Sci 1992, 648:96-104. 10.1111/j.1749-6632.1992.tb24527.x, 1637076.
3. Riederer P, Laux G. MAO-inhibitors in parkinson's disease. Exp Neurobiol 2011, 20:1-17. 10.5607/en.2011.20.1.1, 3213739, 22110357.
4. Gainetdinov R, Fumagalli F, Jones S, Caron M. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1325.
5. Nanhoe-Mahabier W, de Laat K, Visser J, Zijlmans J, de Leeuw F, Bloem B. Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 2009, 10:533-541.
6. Okun M. Deep-brain stimulation for parkinson's disease. N Engl J Med 2012, 367:1529-1538. 10.1056/NEJMct1208070, 23075179.
7. Olanow C, Obeso J, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of parkinson's disease. Nat Clin Pract Neurol 2006, 7:382-392.
8. Hisahara S, Shimohama S. Dopamine receptors and parkinson's disease. Int J Med Chem 2011, 11:1-16.
9. Carlsson A. A paradigmshift in brain research. Science 2001, 294:1021-1024. 10.1126/science.1066969, 11691978.
10. Missale C, Nash S, Robinson S, Jaber M, Caron M. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
11. Kebabian J, Calne D. Multiple receptors for dopamine. Nature 1979, 277:93-96. 10.1038/277093a0, 215920.
12. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980, 32:229-313.
13. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. A targetedmutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996, 93:1945-1949. 10.1073/pnas.93.5.1945, 39888, 8700864.
14. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19:837-848. 10.1016/S0896-6273(00)80965-4, 9354330.
15. Li T, Hou Y, Yan C, Chen T, Zhao Y, Li S. Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci Lett 2010, 485:256-260. 10.1016/j.neulet.2010.09.025, 20849922.
16. Carta A, Gerfen C, Steiner H. Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport 2000, 11:2395-2399. 10.1097/00001756-200008030-00012, 10943692.
17. Schmauss C. A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D1 receptor-mediated neocortical c-fos responses in mice deficient for D2 and D3 receptors. J Biol Chem 2000, 275:38944-38948.
18. Glickstein S, Hof P, Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. Neurosci 2002, 22:5619-5629.
19. D'Agata V, Tiralongo A, Castorina A. Parkin expression profile in dopamine d3 receptor knock-out mice brains. Neurochem Res 2009, 34:327-332. 10.1007/s11064-008-9781-y, 18612813.
20. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of parkinson's disease. Nat Protoc 2007, 2:141-151.
21. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985, 50:435-441.
22. Exner N, Lutz A, Haass C, Winklhofer K. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 2012, 31:3038-3062. 10.1038/emboj.2012.170, 3400019, 22735187.
23. Klein C, Schlossmacher M. The genetics of parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2006, 2:136-146.
24. Yokoyama H, Kuroiwa H, Kasahara J, Araki T. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 2011, 71:269-280.
25. Sagi Y, Weinstock M, Youdim M. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003, 86:290-297.